873697-72-4

Basic information

• Product Name: 1-Piperazinecarboxylic acid, 4-[(3-aminophenyl)methyl]-, methyl ester
• CAS NO: 873697-72-4
• Molecular Formula: C13H19N3O2
• Molecular Weight: 249.313
• Mol File: 873697-72-4.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 1-Piperazinecarboxylic acid, 4-[(3-aminophenyl)methyl]-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperazinecarboxylic acid, 4-[(3-aminophenyl)methyl]-, methyl ester(873697-72-4)
• EPA Substance Registry System: 1-Piperazinecarboxylic acid, 4-[(3-aminophenyl)methyl]-, methyl ester(873697-72-4)

Safety Data

• Hazardous Substances Data: 873697-72-4(Hazardous Substances Data)

Upstream product

• 99-61-6 3-nitro-benzaldehyde 
• 50606-31-0 methyl piperazine-1-carboxylate 
• 1709-44-0 m-aminobenzaldehyde 
• 873697-63-3 C₁₃H₁₇N₃O₄ 

Relevant articles and documents

Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac myosin

We report the design, synthesis, and optimization of the first, selective activators of cardiac myosin. Starting with a poorly soluble, nitro-aromatic hit compound (1), potent, selective, and soluble myosin activators were designed culminating in the discovery of omecamtiv mecarbil (24). Compound 24 is currently in clinical trials for the treatment of systolic heart failure.

CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS

Certain substituted urea derivatives modulate diskeletal myosin, skeletal actin, skeletal tropomyosin, skeletal troponin C, skeletal troponin I, skeletal troponin T, and skeletal muscle, including fragments and isoforms thereof, as well as the skeletal sarcomere, and are useful in the treatment of obesity, sarcopenia, wasting syndrome, frailty, muscle spasm, cachexia, neuromuscular diseases (e.g., amyotrophic lateral sclerosis, spinal muscular atrophy, familial or acquired myopathies or muscular dystrophies), post-surgical and post-traumatic muscle weakness, and other conditions.

CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS

Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.